Tirzepatide versus semaglutide once weekly in patients with Type 2 diabetes, The New England Journal of Medicine (2021) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Tirzepatide once weekly for the treatment of obesity, The New England Journal of Medicine (2022) Mounjaro, tirzepatide injection, solution, DailyMed (2024) Ozempic semaglutide injection, solution, DailyMed (2023) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial, Lancet (2021) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S
This breakthrough medication combines the action of two hormones, GLP-1 and GIP, which regulate your appetite and blood sugar levels
Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation
The better question is whether the patient is medically suitable, whether the treatment is safe for their health profile and whether the plan includes long-term weight maintenance
Haas break down two peptides that are more connected than you'd think KPV for inflammation and gut health, and PT-141 for libido and arousal